Home
overview

Antibody Drug Conjugates (ADCs) offer the promise and potential of delivering powerful tumour-killing activity with the advantage of reduced side effects for cancer patients. While one of the biggest challenges in manufacturing these powerful ADCs is controlling all the components that go into the final conjugation step, researchers do believe that further improvements and research in ADC design can and are resulting in a new generation of agents.
 

Following on from the success of past events,SMI are proud to present 3rd annual Antibody Drug Conjugates Summit, 19th-20th May 2014, London. Focusing on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, this important and timely meeting will bring together key industry experts from academia and large and small pharma and biotech companies.
 

Join us and hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. This must attend event will be delivered by true industry experts who will inform you of latest developments.


Key Topics include:-
• Exploring nano-delivery systems
• Advancing preclinical development to accelerate ADCs into the clinic
• Refining next generation ADCs
• Learn how to overcome manufacturing challenges

 

Previous testimonials include: 

“Good insight into industry knowledge and needs” – University College London

“Some excellent speakers” - Synthon

 

This 2 day networking event will invite in depth discussion of key drivers impacting ADCs, providing a fantastic opportunity to hear from and talk to professionals currently operating in the market. Join the event of the year to:


Hear cutting edge presentations and key case studies from leading ADCs experts
Network and learn from industry and academic opinion leaders
Learn about latest developments pertaining to the components of ADCs (payload, antibody and linker)
Discover what is happening with next generation ADCs

 

Chief Scientific Officer, Heads/Vice Presidents of Drug Discovery, CEO, Senior Scientist, Principal Scientists with responsibility in the following departments:-
• Drug Discovery
• Biologics
• Biologics generation
• Antibody research
• Antibody conjugate development
• Antibody conjugate discovery
• Biomelecular Research
• Genomics Research
• Antibody Engineering
• Protein Sciences
• Protein Technologies
• Bioanalyticcs
• Cell Assays
• Molecular Cell Biology
• Drug Discovery Pharamacology
• Regulatory Affairs
• CMC
• Biotherapeutics
• In Vitro Platfroms
• Antibody and vaccine leads
• Monoclonal Antibody
• Oncology
• Molecular and Translational Medicine
• Tumor Virology
 

ADC Biotechnology; Agensys; Astellas Pharma Technologies Inc; Basel Biotech Manufacturing; Celgene; College Of Physcicians And Surgeons Of Columbia University; Era Consulting (UK) Limited; Genentech; Glythera; GSK; Immunogen; Imperial College London; Maschio & Soames LLP; MedImmune; Medimmune Inc; Merck Serono International S.A.; Merrimack Pharmaceuticals Inc; Morphotek, Inc.; MRCT; Novartis; Pfizer; Photobiotics; PhotoBiotics Ltd; PolyTherics Ltd.; Sanofi Pharma; Spirogen; Swiss Federal Institute Of Technology E T H; Thomson Reuters; UCB S.A; UCL; UCL Biomedica Plc; UCL Cancer Institute; University College London; University of Nottingham; University of Oxford; Viventia Bio Inc.;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Mahendra Deonarain

Mahendra Deonarain, CSO, Photobiotics

9:10 The development of nanobodies and their potential use for ADC

Antonin  de fougerolles

Antonin de fougerolles, Chief Scientific Officer, Ablynx

• An update on the nanobody platform
• Discussing the advantages for ADC
 

9:50 Exploring nano-delivery systems for antibody delivery

Katherine Vallis

Katherine Vallis, Professor of Experimental Radiotherapeutics, University of Oxford

• Learning about the emerging applications of nanotechnologies in ADC.
• Understanding how nanotechnology is at the leading edge of cancer drug delivery due to its emerging features of:
o controlled release
o antibody-driven specificity

10:30 Morning Coffee

10:50 Producing better Antibody-Drug Conjugates (ADCs) using ThioBridge™ Conjugation

George Badescu

George Badescu, Director of Scientific Affairs - Bioconjugation & Protein Engineering, PolyTherics Ltd.

• Site-specific conjugation to disulfide bonds of antibodies and antibody fragments reduces ADC heterogeneity
• ThioBridge™ linkers provide stable conjugates and can be used with a variety of payloads
• ThioBridge™ technology can be used to create novel ADC formats
• In vitro and in vivo data demonstrates good efficacy for mAb and Fab conjugates with an established payload

11:30 Working in perfect harmony - selecting the right target and the right antibody

Adeela Kamal

Adeela Kamal, Associate Director, Medimmune Inc

• Understanding lessons learned from target identification and validation
• Realizing the importance of target expression and internalization
• Reviewing approaches to select a lead ADC: a case study

12:10 Networking Lunch

13:10 Antibody fragment ADCs

Mahendra Deonarain

Mahendra Deonarain, CSO, Photobiotics

• Use of engineered single-chain Fvs
• Light-activated and other payloads
• Comparison with whole antibodies

13:50 Creating effective strategies to reduce toxicity

John Flygare

John Flygare, Project Leader, Discovery Chemistry, Genentech Inc

• Utilizing novel linkers and payloads to improve therapeutic index
• Examining ways to overcome the resistance developed in clinical ADCs
• Using site specific antibody modifications to improve efficacy

14:30 PSMA ADC in prostate cancer: PK/PD analysis from a phase I clinical trial

Hagop  Youssoufian

Hagop Youssoufian, Executive Vice President of R&D , Progenics Pharmaceuticals Inc

• Introducing novel paradigms to assess the therapeutic efficacy in prostate cancer
• Implementing population-based model of longitudinal  PSA measurement from phase I clinical trial
• Correlation of exposure and therapeutic effect

15:10 Afternoon Tea

15:30 Homogeneous and stable ADCs by GlycoConnectTM technology

Floris L van Delft

Floris L van Delft, founder and CSO, Synaffix

• Site-specific, fully stable and homogeneous (DAR = 2.0)
• From any (off-the-shelf) recombinant mAb to ADC in days
• Any IgG / any linker-toxin
• Optional: site-scanning

16:10 Development of second generation duocarmycin ADCs with superior therapeutic window

Ronald  Elgersma

Ronald Elgersma, Project Leader, Antibody-Drug Conjugates, , Synthon BV

• Developing duocarmycin based linker-drug technology
• Conducting preclinical evaluation with in vitro and in vivo studies

16:50 Let’s have a debate! Discussing creative ways to make the ‘smart bomb’ more intelligent when building

Philip Howard

Philip Howard, Chief Scientific Officer, Spirogen

• Discussing latest challenges and improvements to various pieces of the of ADC technology puzzle pertaining to:
o antibodies
o drugs
o linkers that bond them together

17:30 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Adeela Kamal

Adeela Kamal, Associate Director, Medimmune Inc

9:10 The development of the pyrrolobenzodiazepine ADC platform

Philip Howard

Philip Howard, Chief Scientific Officer, Spirogen

• Introduction to the pyrrolobenzodiazepine antitumor antibiotics      
• Pyrrolobenzodiazepine Antibody Conjugates
• Development of synthetic pyrrolobenzodiazepines 

9:50 Fleximer-based ADCs: Overcoming common hurdles

Tim Lowinger

Tim Lowinger, Chief Scientific Officer, Mersana Therapeutics

• Improving DAR without Sacrificing PK and Tolerability
• Maximizing Efficacy of ADCs Targeting Low Expression Targets
• Broadening the Diversity of Payloads Amenable to ADCs

10:30 Morning Coffee

10:50 Addressing tumor heterogeneity and resistance: production of homogeneous bispecific ADCs with combination warheads

Trevor Hallam

Trevor Hallam, Chief Scientific Officer , Sutro Biopharma, Inc.

• Cell–free protein synthesis methods have been developed for production of homogeneous therapeutic proteins, including ADCs
• Many variants can be expressed in hours and rapidly assessed for function.  Within days, production of chosen variants can be scaled using the same platform to generate material for clinical studies.
• The power and utility of the platform to design and manufacture single species bispecific and multispecific antigen-targeted antibodies with conjugated combination warheads will be described

    

11:30 DeBouganin, protein toxin payload with a differentiating mechanism of action

Jeannick  Cizeau

Jeannick Cizeau, Director, Research, Viventia Bio Inc.

• Deimmunized protein payload
• Unique MOA of deBouganin
• In vitro cytotoxicity of various deBouganin drug formats
• Cytotoxicity against cancer stem cells
• Preclinical efficacy
 

12:10 Networking Lunch

13:10 Implementing strategies to ensure successful linker selections for ADCs

Erica Hong

Erica Hong, Scientist,, ImmunoGen, Inc

• Analysing the selection criteria for choosing the right linker technology for ADCs
• Exploring the development of linkers that show improved activity
• Utilizing novel linker molecules

13:50 Arming disease-targeting antibodies with cytotoxic drugs and with cytokines

Giulio Casi

Giulio Casi, Research Scientist, Philochem A G

• Antibody-cytokine fusions: From the bench to the clinic
• Cancer cures with non-internalising antibodies
• Applications of armed antibodies beyond oncology
 

14:30 Afternoon Tea

14:50 Realizing the importance of occupational health and safety in ADC projects

Justin  Mason

Justin Mason, Managing Director, SafeBridge Europe, Limited

• Examining biopharmaceutical compound hazards – biological, small molecule and others
• ADC facility design elements; facilities, layouts and equipment
• Occupational hygiene analytical (bio)chemistry
• Building confidence that the working environment is safe and that containment equipment is working

15:30 Programming the GPS system for maximum target strikes! Evaluating latest approaches for trafficking and binding to the antigen

Nathan Scott

Nathan Scott, Principle Scientist, Global Biotherapeutic Technologies, Wordwide Research & Development, , Pfizer

  • Discussing formats that can assess ADC trafficking from the perspective of:
  • Screening
  • Mechanistic
  • Assessing intracellular trafficking, internalization, and metabolism of the parent antibody
  • Understanding how trafficking processes should allow the use of more stable linkers, which are generally less toxic
  • 16:10 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Adeela Kamal

    Adeela Kamal

    Associate Director, Medimmune Inc
    Erica Hong

    Erica Hong

    Scientist,, ImmunoGen, Inc
    Mahendra Deonarain

    Mahendra Deonarain

    CSO, Photobiotics
    Trevor Hallam

    Trevor Hallam

    Chief Scientific Officer , Sutro Biopharma, Inc.

    Adeela Kamal

    Associate Director, Medimmune Inc
    Adeela Kamal

    Andreas Menrad

    Chief Scientific Officer, Algeta AS
    Andreas Menrad

    Antonin de fougerolles

    Chief Scientific Officer, Ablynx
    Antonin  de fougerolles

    Erica Hong

    Scientist,, ImmunoGen, Inc
    Erica Hong

    Floris L van Delft

    founder and CSO, Synaffix
    Floris L van Delft

    George Badescu

    Director of Scientific Affairs - Bioconjugation & Protein Engineering, PolyTherics Ltd.
    George Badescu

    Giulio Casi

    Research Scientist, Philochem A G
    Giulio Casi

    Hagop Youssoufian

    Executive Vice President of R&D , Progenics Pharmaceuticals Inc
    Hagop  Youssoufian

    Jeannick Cizeau

    Director, Research, Viventia Bio Inc.
    Jeannick  Cizeau

    John Flygare

    Project Leader, Discovery Chemistry, Genentech Inc
    John Flygare

    Justin Mason

    Managing Director, SafeBridge Europe, Limited
    Justin  Mason

    Katherine Vallis

    Professor of Experimental Radiotherapeutics, University of Oxford
    Katherine Vallis

    Mahendra Deonarain

    CSO, Photobiotics
    Mahendra Deonarain

    Nathan Scott

    Principle Scientist, Global Biotherapeutic Technologies, Wordwide Research & Development, , Pfizer
    Nathan Scott

    Philip Howard

    Chief Scientific Officer, Spirogen
    Philip Howard

    Ronald Elgersma

    Project Leader, Antibody-Drug Conjugates, , Synthon BV
    Ronald  Elgersma

    Tim Lowinger

    Chief Scientific Officer, Mersana Therapeutics
    Tim Lowinger

    Trevor Hallam

    Chief Scientific Officer , Sutro Biopharma, Inc.
    Trevor Hallam

    Workshops

    Early Phase Development Considerations for ADCs: Expectations for a First-in-Man
    Workshop

    Early Phase Development Considerations for ADCs: Expectations for a First-in-Man

    Holiday Inn Regents Park
    21st May 2014
    London, United Kingdom

    Interview with Polytherics

    Download

    Interview with Photobiotics

    Download

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.